Enhancing Immunogenicity in Metastatic Melanoma: Adjuvant Therapies to Promote the Anti-Tumor Immune Response

Advanced melanoma is an aggressive form of skin cancer characterized by low survival rates. Less than 50% of advanced melanoma patients respond to current therapies, and of those patients that do respond, many present with tumor recurrence due to resistance. The immunosuppressive tumor-immune microe...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelka, Sandra, Guha, Chandan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452223/
https://www.ncbi.nlm.nih.gov/pubmed/37626741
http://dx.doi.org/10.3390/biomedicines11082245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452223/
https://www.ncbi.nlm.nih.gov/pubmed/37626741
http://dx.doi.org/10.3390/biomedicines11082245

Ejemplares similares